Product image of Molterfin (Buprenorphine) supplied by GNH India

Molterfin

Active Ingredient:
Buprenorphine
Origin:
EU

Molterfin (Buprenorphine)

Buprenorphine, the active ingredient in Molterfin, is a partial mu‑opioid receptor agonist presented as a sublingual formulation for sublingual administration. It provides analgesic effects for moderate to severe pain and helps alleviate withdrawal symptoms in individuals with opioid dependence, offering a ceiling effect that reduces the risk of respiratory depression.\n\nGNH India supplies Molterfin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and regulatory requirements to ensure product integrity across global markets.

Manufacturer / TM Owner

L. Molteni And C. Dei F.Lli Alitti Società Di Esercizio S.P.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Buprenorphine acts on the opioid receptor system and is indicated for the following clinical situations:\n\n- Pain management: provides analgesia for moderate to severe chronic pain, with a ceiling effect on respiratory depression.\n- Opioid dependence treatment: reduces withdrawal symptoms and cravings in patients with opioid use disorder, facilitating maintenance therapy.\n- Palliative care: offers sustained pain relief in terminal illness when other opioids are insufficient.

How It Works

  • Buprenorphine binds with high affinity to mu‑opioid receptors as a partial agonist, producing analgesia while limiting maximal respiratory depression. It simultaneously antagonizes kappa‑opioid receptors, which may contribute to its ability to lessen dysphoria and attenuate opioid withdrawal symptoms. Metabolism occurs primarily via CYP3A4, and the drug’s long receptor occupancy supports its use in maintenance therapy.

Side Effects

  • Buprenorphine may cause a range of adverse reactions, which are categorized by frequency and severity.\n\nCommon Side Effects:\n- Nausea\n- Constipation\n- Headache\n- Dizziness\n- Sedation\n- Dry mouth\n\nSerious or Rare Side Effects:\n- Respiratory depression\n- Severe hypotension\n- QT interval prolongation\n- Adrenal insufficiency\n- Allergic reactions (rash, angioedema)\n- Acute opioid withdrawal if abruptly discontinued

Precautions & Warnings

  • When prescribing or dispensing Molterfin, consider the following precautions:\n\n- Assess respiratory function: monitor patients with compromised breathing or chronic lung disease.\n- Evaluate hepatic function: use caution and consider dose adjustment in severe liver impairment.\n- Avoid concomitant CNS depressants: increased risk of sedation and respiratory depression.\n- Use caution in elderly patients: heightened sensitivity to opioid effects may require lower initial doses.\n- Store at ambient temperature: keep in the original pack, protect from moisture and heat.

Avoid Interactions

  • Buprenorphine can interact with several medication classes; awareness of the interaction level guides clinical decisions.\n\nMajor Interactions (Avoid):\n- CNS depressants (e.g., benzodiazepines, alcohol): additive sedation and respiratory depression.\n- Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase buprenorphine plasma concentrations.\n- Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis.\n\nModerate Interactions (Monitor Closely):\n- CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy.\n- Other opioids: potential for additive opioid effects.\n- Certain antidepressants (e.g., SSRIs, SNRIs): monitor for serotonin syndrome.

Frequently Asked Questions

Molterfin contains buprenorphine and is used to manage moderate to severe chronic pain as well as to treat opioid use disorder by reducing withdrawal symptoms and cravings. It is administered sublingually and is prescribed by qualified healthcare professionals.

Buprenorphine binds strongly to mu‑opioid receptors as a partial agonist, delivering analgesia while limiting maximal respiratory depression. It also blocks kappa‑opioid receptors, which helps lessen dysphoria and contributes to its effectiveness in opioid dependence treatment.

The appropriate dose of Molterfin is individualized and set by the prescribing clinician based on the patient’s condition, prior opioid exposure, and response to therapy. Dosage adjustments follow clinical judgment and monitoring.

Safety data for buprenorphine in pregnancy and lactation are limited. Clinicians weigh potential benefits against risks, and use is generally reserved for situations where alternative therapies are unsuitable. Breastfeeding mothers should discuss risks with their healthcare provider.

To request Molterfin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Both buprenorphine (Molterfin) and methadone are used for opioid dependence, but buprenorphine is a partial mu‑opioid agonist with a ceiling effect on respiratory depression, offering a potentially safer profile. Methadone is a full agonist and may require more intensive monitoring for cardiac effects.

Molterfin should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct heat, and ensure the container is tightly closed when not in use.

Molterfin is administered sublingually. The tablet or film is placed under the tongue and allowed to dissolve completely without swallowing, ensuring optimal absorption through the oral mucosa.

Serious risks include respiratory depression, severe hypotension, QT interval prolongation, adrenal insufficiency, and rare allergic reactions such as angioedema. Patients should be monitored closely for these events, especially when initiating therapy or adjusting doses.

Molterfin is contraindicated in individuals with known hypersensitivity to buprenorphine or any formulation components, in patients receiving opioid antagonists for acute opioid toxicity, and in those with severe respiratory insufficiency not adequately managed. Caution is also advised for patients with significant hepatic impairment.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Buprenorphine

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT